Tissue Diagnostics Market: Unlocking Growth Potential and Addressing Challenges United States of America – October 16, 2025 – The Insight Partners is proud to announce its newest market report, “Tissue Diagnostics Market: An In-depth Analysis of the Tissue Diagnostics Market”. The report provides a holistic view of the tissue diagnostics market and describes the current scenario as well as growth estimates during the forecast period. Explore more - https://www.theinsightpartners.com/reports/tissue-diagnostics-market Overview of the Tissue Diagnostics Market The tissue diagnostics market has been growing steadily, propelled by increasing cancer incidence worldwide, rising demand for precision medicine, technological innovation (digital pathology, AI, automated imaging), and greater healthcare infrastructure investment. Pathology labs, hospitals, and diagnostic centers are increasingly adopting advanced techniques like immunohistochemistry (IHC), in situ hybridization (ISH), and digital tools to enable earlier, more accurate disease diagnosis and better treatment planning. ________________________________________ Key Findings and Insights Market Size and Growth • In 2024, the global tissue diagnostics market was estimated at around USD 8.72 billion. • By 2030, the market is projected to reach approximately USD 14.03 billion, growing at a CAGR of about 8.4% over 2025-2030. Key Factors Affecting the Tissue Diagnostics Market • Rising Prevalence of Chronic Diseases, Especially Cancer: Increasing global incidence of cancer is driving demand for reliable tissue diagnostics. • Growing Geriatric Population: Older populations are more susceptible to cancers and chronic conditions, increasing the need for diagnostic services. • Precision Medicine / Personalized Therapy: The shift toward tailored treatments based on biomarkers and tissue-based diagnostics inflates demand for higher-resolution, reliable diagnostics. • Technology Advancements: Digital pathology, AI/ML tools, automated imaging, better reagents, improved IHC/ISH methods are improving accuracy, speed, and scalability. • Healthcare Spending & Infrastructure Development: Especially in North America and Asia-Pacific, increasing investments in diagnostic capacity, lab infrastructure, and awareness are facilitating market growth. Market Segmentation • By Technology / Technique:  – Immunohistochemistry (IHC) – leading revenue share (~25-26% in 2024)  – In Situ Hybridization (ISH)  – Digital Pathology & Workflow technologies – fastest growing segment in many reports • By Application / Disease Type:  – Breast cancer diagnostics is a major application, holding a large share of tissue diagnostics usage.  – Other cancer types / disease applications following behind. • By End-User / Modality:  – Hospitals and diagnostic centers dominate use cases.  – Research / pharma / Contract Research Organizations (CROs) also significant, especially for novel diagnostics / biomarker discovery. • By Region:  – North America is the largest market by revenue as of 2024.  – Asia-Pacific is among the fastest growing regions, driven by rising healthcare investment and cancer burden. Spotting Emerging Trends Technological Advancements • Integration of AI / Machine Learning with digital pathology for slide scanning, image interpretation, and predictive diagnostics. • Increased automation in IHC/ISH workflows to improve throughput, reduce human error, and speed diagnostics. • Use of novel imaging and multiplexing techniques enabling more biomarkers per tissue sample. Changing Consumer / Institutional Preferences • Demand for faster turnaround times in diagnostic labs. • Preference for non-invasive or minimally invasive diagnostics where possible, though tissue biopsy remains standard. • Growing emphasis on diagnostic accuracy and reliability, particularly for guiding therapy. Regulatory Changes • Increased scrutiny of diagnostic device approval, validation, and compliance, especially for AI-based tools. • Policies promoting early cancer screening, reimbursement programs for diagnostics, which can encourage adoption. • Standards and guidelines evolving for digital pathology and diagnostic data management. Growth Opportunities 1. Digital Pathology and AI Platforms: Companies offering end-to-end digital slide scanning, cloud analytics, and AI-assisted diagnosis can capture growing demand. 2. Biomarker Discoveries and Companion Diagnostics: Tissue diagnostics tied to drug development / therapy matching—especially in oncology—is a promising high‐margin segment. 3. Emerging Markets Expansion: Asia-Pacific, Latin America, and parts of MEA where cancer incidence is rising and diagnostic infrastructure is being upgraded. 4. Improved Workflows and Lab Automation: Products & services that reduce time, cost, and labor for labs (automation, software workflow, remote reading). 5. Consumables & Reagents: Recurrent demand for high-quality reagents, antibodies, probes, slides – making consumables a stable revenue base. 6. Strategic Collaborations and Reimbursement Initiatives: Partnerships between diagnostics firms, hospitals, regulators to expand screening programs; better insurance/reimbursement coverage for advanced diagnostics. Conclusion The Tissue Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2030 report offers essential insights for companies looking to enter or scale in this field. With accelerating disease burden, especially cancer, coupled with technological innovations in digital pathology, AI, imaging, and biomarkers, the tissue diagnostics market is poised for significant growth. Success will depend on balancing regulatory compliance, diagnostic accuracy, speed, and cost-effectiveness. Players that can offer robust, validated technologies and expand into underserved regions while maintaining quality standards are best placed to seize market share in coming years.

Biopsy Devices Market Report: Unlocking Growth Potential and Addressing Challenges United States of America – [October 7, 2025] – The Insight Partners is proud to announce its newest market report, “Biopsy Devices Market: An In-depth Analysis of the Biopsy Devices Industry.” The report provides a holistic view of the Biopsy Devices Market and describes the current scenario as well as growth estimates of the market during the forecast period. ________________________________________ Overview of the Biopsy Devices Market There has been notable development in the Biopsy Devices Market, such as consistent technological improvements and a growing focus on early disease diagnosis. This report provides insight into the driving forces behind this change: technological advancements in minimally invasive procedures, evolving regulatory frameworks, and the increasing prevalence of cancer and other chronic diseases. ________________________________________ Key Findings and Insights Market Size and Growth • The Biopsy Devices Market size is projected to reach US$ 4.59 billion by 2031 from US$ 2.83 billion in 2023. The market is expected to register a CAGR of 6.20% in 2023–2031. The increasing prevalence of cancer cases, increasing number of biopsies, and technological advancements in biopsy devices are likely to remain key Biopsy Devices market trends. • Key Factors Affecting the Biopsy Devices Market: o Increasing incidence of cancer globally, driving diagnostic procedures. o Growing demand for minimally invasive and image-guided biopsy techniques. o Technological innovations in needle design and sampling tools. o Rising awareness and government support for early diagnosis. o Expansion of diagnostic infrastructure in emerging markets. ________________________________________ Market Segmentation • By Product: o Needle-Based Biopsy Guns o Biopsy Guidance Systems o Biopsy Forceps o Localization Wires o Others (Curettes, Punches, etc.) • By Application: o Breast Biopsy o Lung Biopsy o Colorectal Biopsy o Prostate Biopsy o Others • By Technique: o Core Needle Biopsy (CNB) o Fine Needle Aspiration Biopsy (FNAB) o Vacuum-Assisted Biopsy (VAB) • By End User: o Hospitals o Diagnostic & Imaging Centers o Academic & Research Institutes o Ambulatory Surgical Centers • By Region: o North America o Europe o Asia-Pacific o Latin America o Middle East & Africa ________________________________________ Spotting Emerging Trends Technological Advancements • Robotic-assisted biopsy systems for precision targeting. • Integration of AI with imaging to guide biopsies more effectively. • Development of portable and single-use biopsy tools. • Advancements in liquid biopsy as a non-invasive complement to tissue biopsy. Changing Consumer Preferences • Preference for non-invasive and outpatient procedures. • Increased patient awareness about early cancer detection. • Demand for faster diagnosis and turnaround times in pathology results. Regulatory Changes • FDA approvals of new biopsy tools and AI-driven devices. • Standardization of biopsy procedures in oncology guidelines. • Government initiatives encouraging early cancer screening programs. • Reimbursement changes boosting adoption in developing healthcare markets. ________________________________________ Growth Opportunities • Expansion into Emerging Markets: Rising healthcare investments in Asia-Pacific and Latin America offer immense growth potential. • Liquid Biopsy Integration: Complements traditional biopsies for early-stage and recurrent cancer detection. • Home-based Diagnostics: Future integration of at-home sampling for preliminary screening. • Collaborations with Imaging Companies: Cross-industry partnerships are creating integrated diagnostic ecosystems. • Artificial Intelligence: AI-driven tools for biopsy site prediction and real-time procedural assistance. ________________________________________ Conclusion The Biopsy Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023–2031 report provides much-needed insight for any company looking to set up or expand operations in the Biopsy Devices Market. With increasing diagnostic demand, advanced technologies, and global healthcare expansion, the biopsy devices sector is primed for significant growth in the coming years. https://www.theinsightpartners.com/reports/biopsy-devices-market

Monoclonal Antibodies Market Set for Robust Growth Amid Rising Demand for Targeted Therapies The global Monoclonal Antibodies (mAbs) market is poised for significant growth, driven by increasing prevalence of chronic diseases, expanding applications in oncology and autoimmune disorders, and ongoing advancements in biotechnology. The monoclonal antibodies market is projected to reach US$ 243.05 billion by 2028 from US$ 111.01 billion in 2021; it is expected to grow at a CAGR of 11.8% from 2021 to 2028. Monoclonal antibodies have revolutionized treatment modalities due to their high specificity and efficacy in targeting diseased cells, offering promising therapeutic potential across a wide range of indications. Key Market Drivers: • Rising Cancer Incidence: With cancer cases continuing to rise globally, monoclonal antibodies are at the forefront of precision medicine, particularly in immuno-oncology. • Autoimmune and Chronic Diseases: mAbs have proven effective in treating conditions like rheumatoid arthritis, multiple sclerosis, and inflammatory bowel diseases. • Biotechnological Advancements: Innovations such as bispecific antibodies and antibody-drug conjugates (ADCs) are expanding the therapeutic applications of mAbs. • Strategic Collaborations: Pharmaceutical giants are engaging in mergers, acquisitions, and R&D partnerships to expand their biologics pipeline and enhance market presence. Market Segmentation Highlights: • By Type: Human, Humanized, Chimeric, Murine • By Application: Oncology, Autoimmune Diseases, Infectious Diseases, Others • By End User: Hospitals, Specialty Clinics, Research Institutes Regional Insights: North America dominates the market owing to strong healthcare infrastructure, early adoption of novel biologics, and supportive regulatory frameworks. However, the Asia-Pacific region is expected to witness the fastest growth, driven by rising healthcare investments and increasing awareness about advanced therapeutics. Key Players: Prominent companies operating in the monoclonal antibodies market include AbbVie Inc., Amgen Inc., Genentech (Roche), Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca, and Merck & Co., among others. These players are actively focusing on product innovation and clinical trials to sustain competitive advantage. Future Outlook: The monoclonal antibodies market is expected to benefit from the integration of AI in drug discovery, expanding biosimilars market, and growing emphasis on personalized medicine. With a strong pipeline of mAb therapies under development, the market is positioned for transformative growth over the coming decade.

Market Overview The US Telemedicine Market has rapidly expanded in recent years, propelled by technological innovation, changing patient expectations, and increased investment in digital health infrastructure. What began as a solution for remote or underserved populations has evolved into a mainstream modality for all types of care—ranging from primary visits to specialist consultations and chronic disease management. The US telemedicine market size is expected to reach USD 232.4 billion by 2034, according to a new study by Polaris Market Research. This growth reflects ongoing demand for convenience, improved efficiency, and better patient outcomes across care settings. Key Market Growth Drivers 1. Surge in Telehealth Adoption The rise in telehealth adoption has been a driving force in the market’s expansion. Triggered by the COVID-19 pandemic, telemedicine use spiked and has continued to grow as regulatory flexibilities, reimbursement models, and digital literacy have improved. From follow-up visits to mental health therapy, telehealth is now an accepted mode of care delivery. Major healthcare systems, insurers, and employer-sponsored health plans have expanded virtual visit coverage, making it more seamless for patients to choose telemedicine over in-person care for non-emergency needs. 2. Explosion of Remote Patient Monitoring Remote patient monitoring (RPM) has become a key feature of chronic care. Wearable devices, home sensors, and connected health tools enable continuous monitoring of vital signs, glucose levels, blood pressure, and more, feeding real-time data to healthcare teams. RPM platforms have gained reimbursement acceptance and are proving effective in reducing hospitalizations and enhancing care outcomes for conditions like heart failure, diabetes, and COPD. 3. Rise of Virtual Consultations The convenience and accessibility of virtual consultations have reshaped how patients engage with providers. Whether it's behavioral health, dermatology, follow-up care, or even physical therapy, virtual consults reduce barriers such as travel, wait times, and costs. Providers appreciate the operational benefits: shorter visit lengths, flexible scheduling, and better patient connectivity between visits. 4. Focus on Healthcare Accessibility A core driver is improved healthcare accessibility. Telemedicine bridges gaps in rural and underserved areas where specialists are scarce. It also supports access for homebound individuals, busy families, and people with mobility issues. State-level telehealth expansion and broadband investment programs are enabling this transformation, ensuring broader access regardless of geography or socioeconomic status. Market Challenges 1. Regulatory and Reimbursement Complexity Though many pandemic-era restrictions have eased, telemedicine still faces a complex web of compliance requirements—especially across state lines. Providers must navigate licensure issues, variable reimbursement policies, and rules around tele-prescribing. Lack of federal licensing reciprocity continues to hinder national practice expansion. 2. Technology Barriers and Digital Divide Despite progress, a digital divide persists. Rural regions and economically disadvantaged communities may lack reliable broadband, modern devices, or digital literacy. This hampers universal access and limits telemedicine's potential in equity-driven healthcare goals. 3. Clinical Limitations and Patient Preferences Certain care types—such as physical exams, acute interventions, and procedures—still require in-person visits. Some clinicians and patients prefer face-to-face interaction, or encounter limitations in technology quality (e.g., poor video quality, inability to perform physical tests remotely). 4. Data Privacy and Security Concerns As telemedicine expands, safeguarding patient data is critical. Robust and standardized frameworks around encryption, authentication, and incident response are needed to maintain trust. Breaches or poor security practices can derail telehealth adoption. 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞: https://www.polarismarketresearch.com/industry-analysis/us-telemedicine-market